

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders' Annual General Meeting at the company's premises on May 14, 2024. A total of 30,133,104 shares were represented at the Annual General Meeting, corresponding to 66.61% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.

Adoption of the accounts

The Annual General Meeting adopted the balance sheet and income statement for the period 2023-01-01 – 2023-12-31.

Disposition of financial results

The Annual General Meeting resolved, in accordance with the Board of Director's proposal, that the loss for the year be distributed according to the balance sheet.

Discharge from liability

The members of the Board of Directors and the CEO were discharged from liability.

Remuneration and auditors fees

Remuneration to the Board of Directors and auditors was resolved as follows:

- Remuneration to the Chairman of the Board is SEK 325,000 for the period until next AGM.
- Remuneration to other board members, who are not principal owners, is SEK 225,000 for the period until next AGM.
- Remuneration to the auditor is paid against invoice, after approval by the company.

Board of Directors and auditor

Board members Olof Sandén, Martin Ingvar and Magne Jordanger were re-elected as board members. Grant Thornton Sweden AB was re-elected as audit firm with Joakim Söderin as acting auditor.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com) or visit <https://www.inify.com>

About Inify Laboratories

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from [ContextVision](#), with 40 years of experience within digital imaging for medical applications. It is listed on [Euronext Growth Oslo](#) under the ticker [INIFY](#).

This information is subject to the disclosure requirements of sections 5-12 of the Norwegian Securities Trading Act.